Cancer types
  • Neuro-oncology
Title of study
Glioblastoma, Optimizing Logistics and Dose (GOLD)
Version Number
Approval Date 
2.0, 11-05-2020
Short Title
Study site
Principle Investigator
J. Verhoeff
Investigator Maastro
D. Eekers
UMC Utrecht
Trial registry

To test whether extremely hypofractionated radiotherapy (6 x 6 Gy) is non-inferior to standard radiotherapy (30 x 2 Gy) in terms of overall survival in patients with newly diagnosed GBM. Secondary objectives are to establish and compare health related quality of life (HRQoL), cost-effectiveness, toxicity and progression-free survival in both treatment arms.

Primary Endpoint 

To compare overall survival of conventional chemoradiotherapy (30 x 2 Gy) with that of hypofractionated chemoradiotherapy (6 x 6 Gy), both combined with concomitant and sequential temozolomide chemotherapyin newly diagnosed GBM patients.

Secondary Endpoints 

1.To compare toxicity between the two treatment groups.
2.To compare progression free survival between the two treatment groups.
3.To compare health related quality of life (HRQoL) between the two treatment groups.
4.To perform a cost utility analysis by comparing the effects and costs with regard toutilization of hospital resources, personal patient medical consumption costs and productivity costs.